UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March, 2016
Commission File Number: 000-36000
XTL
Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
5 HaCharoshet St.,
Raanana 4365603
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No.
333-148085, File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).
LUPUS
THOUGHT LEADER daphna paran, md, named medical
director of xtl biopharmaceuticals
World
renowned expert in the treatment of lupus with over 60 published articles
and extensive clinical trial experience
RAANANA,
Israel - (March 9, 2016) – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB,
TASE: XTLB.TA) (“XTL” or the “Company”), a clinical-stage biopharmaceutical company developing its
lead product for the treatment of lupus, today announced the appointment of Dr. Daphna Paran, an internal medicine and rheumatology
specialist, as Medical Director.
“Dr. Paran has significant experience
in the treatment of lupus patients, has published extensively on the subject, and has been involved in several clinical studies
in the search for viable treatment options for this difficult disease,” said Josh Levine, CEO of XTL. “We are excited
to welcome her aboard as our Medical Director as we enter the next phase of developing our lead drug candidate hCDR1 for the treatment
of systemic lupus erythematosus (SLE). Having received encouraging feedback from the U.S. Food and Drug Administration on our proposed
clinical trial, we are now completing the Phase II protocol design with Dr. Paran’s guidance and anticipate initiating the
trial in the second half of 2016.”
Dr. Paran has over 20 years of rheumatology
expertise with a focus on lupus. She is a senior lecturer at Tel Aviv University, the head of the lupus clinic, head of the rheumatology
day care unit and the deputy head of the Department of Rheumatology at the Tel Aviv Medical Center (Ichilov Hospital). She completed
her medical studies at Ben Gurion University, trained in lupus and the antiphospholipid syndrome at the lupus unit, Rayne Institute,
St. Thomas' Hospital in London and has published or co-authored over 60 articles in the field of lupus and rheumatology.
“I am privileged to join the team
as Medical Director of XTL to lend my experience to the advancement of what I believe to be a very promising lupus drug candidate,”
stated Dr. Paran. “hCDR1 showed very promising data in the prior Phase 2b trial. If we are able to duplicate these results
utilizing well defined primary endpoints in our next clinical study we could have a promising solution to a largely unmet medical
need. I and the rest of the medical community in this field are eagerly waiting to learn the efficacy of this drug in the upcoming
trial.”
About hCDR1
hCDR1
is a novel compound with a unique mechanism of action and has clinical data on over 400 patients in three clinical studies. The
drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful
endpoint. For more information please see a peer
reviewed article in Lupus Science and Medicine journal (http://lupus.bmj.com/content/2/1/e000104.full).
XTL Biopharmaceuticals Ltd. |
|
5 Hacharoshet Street, Raanana, 43656, Israel |
Page 1 |
Tel: +972 9 955 7080; email: ir@xtlbio.com |
|
About Systemic Lupus Erythematosus (SLE)
Lupus is a chronic autoimmune disease involving
many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system and others. The
biologic basis of the disease is a defect in the immune (defense) system, leading to production of self (auto) antibodies, attacking
the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least 1.5 million Americans
have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The majority of patients
are women of childbearing years. There has been only one drug approved by the FDA in the last 50 years and recently two of the
few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.
About XTL Biopharmaceuticals Ltd.
(XTL)
XTL Biopharmaceuticals
Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of
systemic lupus erythematosus (SLE). There currently is no effective treatment on the market for SLE. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer
reviewed scientific journals. Based on encouraging safety and efficacy data shown in a completed Phase 2 study, the Company
expects to initiate a Phase 2 trial in 2016.
XTL is traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080
Email: ir@xtlbio.com
www.xtlbio.com
========================================================================================================
XTL Biopharmaceuticals Ltd. |
|
5 Hacharoshet Street, Raanana, 43656, Israel |
Page 2 |
Tel: +972 9 955 7080; email: ir@xtlbio.com |
|
![](http://www.sec.gov/Archives/edgar/data/1023549/000114420416086776/xtlbiologo.jpg)
Cautionary Statement
This press release may contain forward-looking
statements, about XTL’s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as "believe," "expect," "intend," "plan," "may,"
"should" or "anticipate" or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL’s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL’s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL’s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL’s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Registration Statement on Form F-1 as filed
with the U.S. Securities and Exchange Commission on December 31, 2015.
XTL Biopharmaceuticals Ltd. |
|
5 Hacharoshet Street, Raanana, 43656, Israel |
Page 3 |
Tel: +972 9 955 7080; email: ir@xtlbio.com |
|
SIGNATURES.
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
XTL BIOPHARMACEUTICALS LTD. |
|
|
|
|
|
|
|
By: |
/s/ Josh Levine |
|
Date: March
9, 2016 |
|
Josh Levine |
|
|
Chief Executive Officer |
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024